Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription Articles published in Mol Cancer Ther Retrieve available abstracts of 24 articles: HTML format

Single Articles

May 2025
1. OKAWA S, Tomida S, Kuribayashi T, Nishimura J, et al
   Colony-stimulating factor-1 receptor inhibitor augments osimertinib-induced anti-tumor immunity via suppression of macrophages in lung cancer harboring EGFR mutation.
   Mol Cancer Ther. 2025 May 29. doi: 10.1158/1535-7163.MCT-25-0002.
   PubMed     Abstract available
   
   
   April 2025
2. DOMINGUEZ-VIGIL IG, Banik K, Baro M, Contessa JN, et al
   PLK4 inhibition as a strategy to enhance non-small cell lung cancer radiosensitivity.
   Mol Cancer Ther. 2025 Apr 29. doi: 10.1158/1535-7163.MCT-24-0978.
   PubMed     Abstract available
   
   
   
3. YUAN R, McGeehan A, Zhou S, Cheng C, et al
   The anti-FRalpha antibody-drug conjugate luveltamab tazevibulin demonstrates efficacy in non-small cell lung cancer preclinical models and induces immunogenic cell death.
   Mol Cancer Ther. 2025 Apr 28. doi: 10.1158/1535-7163.MCT-24-0649.
   PubMed     Abstract available
   
   
   March 2025
4. KOGAI H, Tsukamoto S, Koga M, Miyano M, et al
   Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody-Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models.
   Mol Cancer Ther. 2025;24:392-405.
   PubMed     Abstract available
   
   
   
5. KIM DK, Synn CB, Lee W, Jo HN, et al
   Denfivontinib Activates Effector T Cells Through the NLRP3 Inflammasome, Yielding Potent Anticancer Effects by Combination with Pembrolizumab.
   Mol Cancer Ther. 2025;24:354-369.
   PubMed     Abstract available
   
   
   January 2025
6. LU S, Pan X, Volckova E, Shinde A, et al
   Targeting Monounsaturated Fatty Acid Metabolism for Radiosensitization of KRAS Mutant 3D Lung Cancer Models.
   Mol Cancer Ther. 2025 Jan 21. doi: 10.1158/1535-7163.MCT-24-0213.
   PubMed     Abstract available
   
   
   December 2024
7. CALLES A, Calvo E, Santamaria Nunez G, Costanzo F, et al
   Unveiling the Mechanism of Lurbinectedin's Action and Its Potential in Combination Therapies in Small Cell Lung Cancer.
   Mol Cancer Ther. 2024 Dec 5. doi: 10.1158/1535-7163.MCT-24-0050.
   PubMed     Abstract available
   
   
   
8. MARTIN-VEGA A, Earnest SA, Augustyn A, Wichaidit C, et al
   ASCL1 Restrains ERK1/2 to Promote Survival of a Subset of Neuroendocrine Lung Cancers.
   Mol Cancer Ther. 2024;23:1789-1800.
   PubMed     Abstract available
   
   
   November 2024
9. OH MS, Dumitras C, Salehi-Rad R, Tran LM, et al
   Characteristics of a CCL21-gene modified dendritic cell vaccine utilized for a clinical trial in non-small cell lung cancer.
   Mol Cancer Ther. 2024 Nov 19. doi: 10.1158/1535-7163.MCT-24-0435.
   PubMed     Abstract available
   
   
   October 2024
10. CINA C, Majeti B, O'Brien Z, Wang L, et al
    A Novel Lipid Nanoparticle NBF-006 Encapsulating Glutathione S-Transferase P siRNA for the Treatment of KRAS-driven Non-small Cell Lung Cancer.
    Mol Cancer Ther. 2024 Oct 17. doi: 10.1158/1535-7163.MCT-23-0915.
    PubMed     Abstract available
    
    
    
11. GUO Q, Gao B, Song R, Li W, et al
    FZ-AD005, a Novel DLL3-Targeted Antibody-Drug Conjugate with Topoisomerase I Inhibitor, Shows Potent Antitumor Activity in Preclinical Models.
    Mol Cancer Ther. 2024;23:1367-1377.
    PubMed     Abstract available
    
    
    August 2024
12. DAVE F, Vaghela P, Heath B, Dunster Z, et al
    SC134-TCB targeting fucosyl-GM1, a T cell engaging antibody with potent anti-tumour activity in preclinical small-cell lung cancer models.
    Mol Cancer Ther. 2024 Aug 26. doi: 10.1158/1535-7163.MCT-24-0187.
    PubMed     Abstract available
    
    
    
13. RODRIGUEZ BL, Huang J, Gibson L, Fradette JJ, et al
    Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors.
    Mol Cancer Ther. 2024;23:1144-1158.
    PubMed     Abstract available
    
    
    May 2024
14. XU Y, Ding K, Peng Z, Ding L, et al
    Evaluating for Correlations between Specific Metabolites in Patients Receiving First-Line or Second-Line Immunotherapy for Metastatic or Recurrent NSCLC: An Exploratory Study Based on Two Cohorts.
    Mol Cancer Ther. 2024;23:733-742.
    PubMed     Abstract available
    
    
    
15. MA W, Wei S, Li Q, Zeng J, et al
    Simvastatin Overcomes Resistance to Tyrosine Kinase Inhibitors in Patient-derived, Oncogene-driven Lung Adenocarcinoma Models.
    Mol Cancer Ther. 2024;23:700-710.
    PubMed     Abstract available
    
    
    April 2024
16. LULLA AR, Akli S, Karakas C, Caruso JA, et al
    Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis.
    Mol Cancer Ther. 2024;23:492-506.
    PubMed     Abstract available
    
    
    March 2024
17. MCCRURY M, Swafford K, Shuttleworth SL, Mehdi SH, et al
    Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma.
    Mol Cancer Ther. 2024;23:316-329.
    PubMed     Abstract available
    
    
    February 2024
18. HIRAI S, Yamada T, Katayama Y, Ishida M, et al
    Effects of Combined Therapeutic Targeting of AXL and ATR on Pleural Mesothelioma Cells.
    Mol Cancer Ther. 2024;23:212-222.
    PubMed     Abstract available
    
    
    January 2024
19. CHEN N, Tyler LC, Le AT, Welsh EA, et al
    MIG6 Mediates Adaptive and Acquired Resistance to ALK/ROS1 Fusion Kinase Inhibition through EGFR Bypass Signaling.
    Mol Cancer Ther. 2024;23:92-105.
    PubMed     Abstract available
    
    
    
20. HILLEN H, Candi A, Vanderhoydonck B, Kowalczyk W, et al
    A Novel Irreversible TEAD Inhibitor, SWTX-143, Blocks Hippo Pathway Transcriptional Output and Causes Tumor Regression in Preclinical Mesothelioma Models.
    Mol Cancer Ther. 2024;23:3-13.
    PubMed     Abstract available
    
    
    December 2023
21. GUAN C, Zhang X, Yu L
    A review of recent advances in the molecular mechanisms underlying brain metastasis in lung cancer.
    Mol Cancer Ther. 2023 Dec 20. doi: 10.1158/1535-7163.MCT-23-0416.
    PubMed     Abstract available
    
    
    
22. OGIMOTO T, Ozasa H, Tsuji T, Funazo T, et al
    Combination therapy with EGFR tyrosine kinase inhibitors and TEAD inhibitor increases tumor suppression effects in EGFR mutation-positive lung cancer.
    Mol Cancer Ther. 2023 Dec 6. doi: 10.1158/1535-7163.MCT-23-0371.
    PubMed     Abstract available
    
    
    
23. KHAN HY, Nagasaka M, Aboukameel A, Alkhalili O, et al
    Anticancer Efficacy of KRASG12C Inhibitors Is Potentiated by PAK4 Inhibitor KPT9274 in Preclinical Models of KRASG12C-Mutant Pancreatic and Lung Cancers.
    Mol Cancer Ther. 2023;22:1422-1433.
    PubMed     Abstract available
    
    
    September 2023
24. WENG W, Meng T, Pu J, Ma L, et al
    AMT-562, a Novel HER3-targeting Antibody-Drug Conjugate, Demonstrates a Potential to Broaden Therapeutic Opportunities for HER3-expressing Tumors.
    Mol Cancer Ther. 2023;22:1013-1027.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.